Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells

Molecular Cancer

Volumn 2, Issue , 2003, Pages

  Riedl, Karen ^a   Baratelli, Felicita ^a   Batra, Raj K ^a,b   Yang, Seok Chul ^a   Luo, Jie ^a   Escuadro, Brian ^a   Figlin, Robert ^a   Strieter, Robert ^a   Sharma, Sherven ^a,b   Dubinett, Steven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CHEMOKINE; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CCL21 PROTEIN, HUMAN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER THERAPY; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOCYTE MIGRATION; MONOCYTE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; UPREGULATION; ADENOVIRUS; BIOSYNTHESIS; CELL MOTION; CHEMOTAXIS; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE; METABOLISM; PHYSIOLOGY;

MURINAE;

ADENOVIRIDAE; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; CELL MOVEMENT; CHEMOKINE CCL21; CHEMOKINES, CC; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTES; TRANSFECTION;

EID: 2942557230     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-2-35     Document Type: Article

References (52)

1. Huang A, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D and Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264:961-965.
2. Restifo N, Esquivel F, Kawakami Y, Yewdell J, Mule J, Rosenberg S and Bennink J: Identification of human cancers deficient in antigen processing. J Exp Med 1993, 177:265-272.
3. Banchereau J and Steinman R: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
4. Timmerman J and Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50:507-529.
5. Mukherji B, Chakraborty N, Yamasaki S, Okino T, Yamase H, Sporn J, Kurtzman S, Ergin M, Ozols J and Meehan J: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995, 92:8078-8082.
6. Murphy G, Tjoa B, Simmons S, Ragde H, Rogers M, Elgamal A, Kenny G, Troychak M, Salgaller M and Boynton A: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999, 39:5459.
7. Lodge P, Jones L, Bader R, Murphy G and Salgaller M: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000, 60:829-833.
8. Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
9. Miller P, Sharma S, Stolina M, Chen K, Zhu L, Paul RW and Dubinett S: Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 1998, 5:380-389.
10. Sharma S, Miller P, Stolina M, Zhu L, Huang M, Paul R and Dubinett S: Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7 / Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Therapy 1997, 4:1361-1370.
11. Mayordomo J, Loftus D, Sakamoto H, De Cesare C, Appasamy P, Lotze M, Storkus W, Appella E and DeLeo A: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996, 183:1357-1365.
12. Henderson R, Nimgaonkar M, Watkins S, Robbins P, Ball E and Finn O: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996, 56:3763-3770.
13. Ribas A, Butterfield L, McBride W, Jilani S, Bui L, Vollmer C, Lau R, Dissette V, Hu B, Chen A, Glaspy J and Economou J: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997, 57:2865-2869.
14. Ribas A, Bui L, Butterfield L, Vollmer C, Jilani S, Dissette V, Glaspy J, McBride W and Economou J: Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 1999, 19:1165-1170.
15. Celluzzi C and Falo L: Cutting edge: Physical interaction between dendritic cells and tumor cells result in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998, 160:3081-3085.
16. Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H and Wang J: Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998, 161:6238-6244.
17. Miller P, Sharma S, Stolina M, Butterfield L, Luo J, Lin Y, Dohadwala M, Batra R, Wu L, Economou J and Dubinett S: Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000, 11:53-65.
18. Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S and Pisa P: Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther 2002, 13:1541-1549.
19. Miller G, Lahrs S, Pillarisetty V, Shah A and DeMatteo R: Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002, 62:5260-5266.
20. Kirk C, Hartigan-O'Connor D, Nickoloff B, Chamberlain J, Giedlin M, Aukerman L and Mule J: T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001, 61:2062-2070.
21. Kirk C, Hartigan-O'Connor D and Mule J: The Dynamics of the T Cell Antitumor Response: Chemokine-secreting Dendritic Cells Can Prime Tumor-reactive T Cells Extranodally. Cancer Res 2001, 61:8794-8802.
22. Nishioka Y, Hirao M, Robbins P, Lotze M and Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999, 59:4035-4041.
23. Riedl K, Baratelli F, Yang S, Luo J, Escuadro B, Batra R, Figlin R, Strieter R, Sharma S and Dubinett S: Characterization of adenoviral CCL21/SLC for intratumoral dendritic cell (DC) based therapies in NSCLC [Abstract 1834]. Proc AACR 2003, 44:417.
24. Rollins B: Chemokines. Blood 1997, 90:909-928.
25. Baggiolini M, Dewald B and Moser B: Human chemokines: an update. Annu Rev Immunol 1997, 15:675-705.
26. Cyster J: Chemokines and the Homing of Dendritic Cells to the T Cell Areas of Lymphoid Organs. J Exp Med 1999, 189:447-450.
27. Ogata M, Zhang Y, Wang Y, Itakura M, Zhang Y, Harada A, Hashimoto S and Matsushima K: Chemotactic Response Toward Chemokines and Its Regulation by Transforming Growth Factor-beta1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells. Blood 1999, 93:3225-3232.
28. Chan V, Kothakota S, Rohan M, Panganiban-Lustan L, Gardner J, Wachowicz J, Winter M and Williams L: Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 1999, 93:3610-3616.
29. Hedrick J and Zlotnik A: Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol 1997, 159:1589-1593.
30. Hromas R, Kim C, Klemsz M, Krathwohl M, Fife K, Cooper S, Schnizlein-Bick C and Broxmeyer H: Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol 1997, 159:2554-2558.
31. Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H and Yoshie O: Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J Biol Chem 1997, 272:19518-19524.
32. Tanabe S, Lu Z, Luo Y, Quackenbush E, Berman M, Collins-Racie L, Mi S, Reilly C, Lo D, Jacobs K and Dorf M: Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol 1997, 159:5671-5679.
33. Willimann K, Legler D, Loetscher M, Roos R, Delgado M, Clark-Lewis I, Baggiolini M and Moser B: The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998, 28:2025-2034.
34. Gunn M, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams L and Nakano H: Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999, 189:451-460.
35. Soto H, Wang W, Strieter R, Copeland N, Gilbert D, Jenkins N, Hedrick J and Zlotnik A: The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci U S A 1998, 95:8205-8210.
36. Sharma S, Stolina M, Luo J, Strieter R, Burdick M, Zhu L, Batra R and Dubinett S: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000, 164:4558-4563.
37. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R and Dubinett S: Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001, 61:6406-6412.
38. Nishimura N, Nishioka Y, Shinohara T, Ogawa H, Yamamoto S, Tani K and Sone S: Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J Immunol Methods 2001, 253:113-124.
39. Nishimura N, Nishioka Y, Shinohara T and Sone S: Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther 2001, 12:333-346.
40. Hirschowitz E, Weaver J, Hidalgo G and Doherty D: Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 2000, 7:1112-1120.
41. Morelli A, Larregina A, Ganster R, Zahorchak A, Plowey J, Takayama T, Logar A, Robbins P, Falo L and Thomson A: Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 2000, 74:9617-9628.
42. Christopherson K 2nd, Campbell J and Hromas R: Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood 2001, 98:3562-3568.
43. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E and Lipp M: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
44. Huang M, Stolina M, Sharma S, Mao J, Zhu L, Miller P, Wollman J, Herschman H and Dubinett S: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998, 58:1208-1216.
45. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G and Rodeck U: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999, 155:537-547.
46. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
47. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay C, Qin S and Lanzavecchia A: Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998, 28:2760-2769.
48. Kellermann S, Hudak S, Oldham E, Liu Y and McEvoy L: The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999, 162:3859-3864.
49. Rieser C, Ramoner R, Holtl L, Rogatsch H, Papesh C, Stenzl A, Bartsch G and Thurnher M: Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 1999, 63:151-159.
50. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Brocker E, Enk A, Kampgen E and Schuler G: Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000, 165:3492-3496.
51. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge T, Paragnik L, Kandemir A, Lee P, Schuler G, Knop J and Enk A: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001, 93:243-251.
52. Whittaker D, Bahjat K, Moldawer L and Clare-Salzler M: Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J Immunol 2000, 165:4298-4304.